Should alectinib or ceritinib be given as first line therapy for ALK positive non-small cell lung cancer patients instead of crizotinib?

Research output: Contribution to journalEditorialAcademicpeer-review

Original languageEnglish
Pages (from-to)S1010-S1013
JournalTranslational Cancer Research
Volume6
DOIs
Publication statusPublished - 1 Aug 2017

Cite this

@article{5a950d425fd0404cbee4a5c6c2b10b20,
title = "Should alectinib or ceritinib be given as first line therapy for ALK positive non-small cell lung cancer patients instead of crizotinib?",
author = "Peters, {Godefridus J.} and Muller, {Ittai B.} and Elisa Giovannetti",
year = "2017",
month = "8",
day = "1",
doi = "10.21037/tcr.2017.06.54",
language = "English",
volume = "6",
pages = "S1010--S1013",
journal = "Translational lung cancer research",
issn = "2218-6751",
publisher = "Society for Translational Medicine (STM)",

}

TY - JOUR

T1 - Should alectinib or ceritinib be given as first line therapy for ALK positive non-small cell lung cancer patients instead of crizotinib?

AU - Peters, Godefridus J.

AU - Muller, Ittai B.

AU - Giovannetti, Elisa

PY - 2017/8/1

Y1 - 2017/8/1

UR - http://www.scopus.com/inward/record.url?scp=85028502472&partnerID=8YFLogxK

U2 - 10.21037/tcr.2017.06.54

DO - 10.21037/tcr.2017.06.54

M3 - Editorial

VL - 6

SP - S1010-S1013

JO - Translational lung cancer research

JF - Translational lung cancer research

SN - 2218-6751

ER -